文献速递浆细胞疾病MDS 与骨髓增殖性肿瘤

全基因组筛选鉴定来那度胺依赖性CRL4CRBN活性所需的cullin-RING连接酶机制

Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity.
PubMed 文献 · Blood · 2018-07-24

研究通过CRISPR-Cas9全基因组筛选在来那度胺敏感骨髓瘤细胞系中鉴定来那度胺诱导CRL4CRBN活性所需的细胞机制,发现CRBN为最高评分基因,并明确UBE2M、COP9信号体、UBE2D3和UBE2G1在来那度胺诱导蛋白降解中的作用。

要点

  • CRBN为筛选最高评分基因,所有靶向CRBN的gRNA位列前6高评分gRNA。
  • UBE2M或COP9信号体成员缺失改变cullin 4A的neddylation并损害来那度胺依赖性CRL4CRBN活性。
  • UBE2D3和UBE2G1在CRL4CRBN底物泛素化中作用不同:UBE2D3介导单泛素化启动,UBE2G1延伸K48连接多泛素链。

核心结论

  • 研究鉴定了骨髓瘤中来那度胺依赖性CRL4CRBN功能所需的关键蛋白,并提示潜在的耐药机制。

研究设计与样本

  • 在来那度胺敏感骨髓瘤细胞系中进行正选择全基因组CRISPR-Cas9筛选,并使用IKZF3 degron报告基因进行反筛选。

主要发现

  • CRBN是排名最高的基因,所有靶向CRBN的gRNA位列6个最高评分gRNA。
  • 反筛选突出显示cullin-RING连接酶neddylation调节因子和2个E2泛素结合酶为来那度胺诱导蛋白降解所必需。
  • UBE2M或COP9信号体成员缺失导致cullin 4A neddylation改变并损害来那度胺依赖性CRL4CRBN活性。
  • UBE2D3通过单泛素化启动靶标,UBE2G1通过赖氨酸48连接延伸多泛素链。

关键数值与推荐

  • CRBN-targeting gRNAs排名:所有CRBN靶向gRNA为6个最高评分gRNA。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lenalidomide mediates the ubiquitination and degradation of Ikaros family zinc finger protein 1 (IKZF1), IKZF3, and casein kinase 1α (CK1α) by facilitating their interaction with cereblon (CRBN), the substrate receptor for the CRL4CRBN E3 ubiquitin ligase. Through this mechanism, lenalidomide is a clinically effective treatment of multiple myeloma and myelodysplastic syndrome (MDS) with deletion of chromosome 5q [del(5q) MDS]. To identify the cellular machinery required for lenalidomide-induced CRL4CRBN activity, we performed a positive selection, genome-scale clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) screen in a lenalidomide-sensitive myeloma cell line. CRBN was the top-ranking gene, with all CRBN-targeting guide RNAs (gRNAs) ranking as the 6 highest-scoring gRNAs. A counterscreen using an IKZF3 degron reporter to assay lenalidomide-induced protein degradation highlighted regulators of cullin-RING ligase neddylation and 2 E2 ubiquitin-conjugating enzymes as necessary for efficient lenalidomide-induced protein degradation. We demonstrated that loss of UBE2M or members of the constitutive photomorphogenesis 9 (COP9) signalosome results in altered neddylation of cullin 4A and impairs lenalidomide-dependent CRL4CRBN activity. Additionally, we established that UBE2D3 and UBE2G1 play distinct roles in substrate ubiquitination by CRL4CRBN, with UBE2D3 acting to prime targets via monoubiquitination and UBE2G1 functioning to extend polyubiquitin chains with lysine 48 linkages. The validation of UBE2D3 and UBE2G1 highlights the functional capacity of CRISPR-Cas9 screening to identify E2 ubiquitin-conjugating enzyme and E3 ubiquitin ligase complex pairings. More broadly, these findings establish key proteins required for lenalidomide-dependent CRL4CRBN function in myeloma and inform potential mechanisms of drug resistance.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sievers QL, Gasser JA, Cowley GS, et al. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood. 2018. PMID: 30042095. doi:10.1182/blood-2018-01-821769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。